News
Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge cancer care closer to patients in ...
During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...
Northwell Health unveiled a $1.1 million, 2,400-square-foot expansion of outpatient infusion at the R.J. Zuckerberg Cancer ...
Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification
Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...
MUSC research to use he immune system to fight cancer shows it can be done safer, cheaper and better. An SC company pushing ...
"I won't hold my breath, because most of my patients do relapse at some point, but I was really excited about this curve when ...
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...
A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...
Autolus Therapeutics plc delivers a breakthrough CAR-T therapy for B-ALL with strong safety/efficacy. Learn more about AUTL ...
Most caregivers and two-thirds of patients report experienced financial toxicity related to CAR-T therapy, but not associated with CRS or CR on day 28.
The field of Cancer Immunity & Immunotherapy is entering an exciting new phase. While Volume I (see here) of this Research Topic highlighted broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback